Cited by 124Neuroinflammation and Neurodegeneration MechanismsSingle-cell and spatial transcriptomicsMultiple Sclerosis Research Studies

The Human Microglia Atlas (HuMicA) unravels changes in disease-associated microglia subsets across neurodegenerative conditions

Open access
Martins-Ferreira, Ricardo, Calafell-Segura, Josep, Leal, Bárbara, Rodríguez-Ubreva, Javier, Martínez-Saez, Elena, Mereu, Elisabetta, Pinho E Costa, Paulo, Laguna, Ariadna +1 more·2025·Nature Communications

Published version of a preprint

Abstract

ABSTRACT Dysregulated microglia activation, leading to neuroinflammation, is crucial in neurodegenerative disease development and progression. The initial M1/M2 dual activation classification for microglia is outdated. Even the ‘disease-associated microglia’ (DAM) phenotype, firstly described in mice, falls short in representing the diverse microglia phenotypes in pathology. In this study, we have constructed a transcriptomic atlas of human brain immune cells by integrating single-nucleus (sn)RNA-seq datasets from multiple neurodegenerative conditions. Sixteen datasets were included, comprising 295 samples from patients with Alzheimer’s disease, autism spectrum disorder, epilepsy, multiple sclerosis, Lewy body diseases, COVID-19, and healthy controls. The integrated Human Microglia Atlas ( HuMicA ) dataset included 60,557 nuclei and revealed 11 microglial subpopulations distributed across all pathological and healthy conditions. Among these, we identified four different homeostatic clusters as well as pathological phenotypes. These included two stages of early and late activation of the DAM phenotype and the disease-inflammatory macrophage (DIM) phenotype, which was recently described in mice, and is also present in human microglia, as indicated by our analysis. The high versatility of microglia is evident through changes in subset distribution across various pathologies, suggesting their contribution in shaping pathological phenotypes. Our analysis showed overall depletion of four substates of homeostatic microglia, and expansion of niche subpopulations within the DAM and DIM spectrum across distinct neurodegenerative pathologies. The HuMicA is invaluable in advancing the study of microglia biology in both healthy and disease settings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-025-56124-1

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many disease-associated microglial programs are spatially enriched around plaques, suggesting microglial state transitions are disease-stage-dependent and anatomically localized.

    “Many disease-associated microglial programs are spatially enriched around plaques, which suggests that microglial state transitions are not only disease-stage-dependent but also anatomically localized.”

    From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [47]

    The Results section (‘Pathology-associated alterations in microglia subpopulations’; page unavailable) describes qualitative colocalization of GPNMB-high microglia with potential amyloid plaques in Alzheimer’s disease samples. It does not establish that many disease-associated programs are enriched around plaques or that microglial state transitions depend on disease stage. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Microglia in Alzheimer's disease occupy multiple transcriptional trajectories rather than discrete and permanent categories.

    “Large human microglial atlases and state-dynamics studies are beginning to show that microglia in Alzheimer’s disease occupy multiple transcriptional trajectories rather than discrete and permanent categories [22,47].”

    From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [47]

    The Introduction (page unavailable) says that M1/M2 and disease-associated microglia categories do not capture microglial complexity, and that microglial plasticity may follow a multi-subpopulation pattern. The Discussion (page unavailable) reports transcriptionally distinct groups, including populations altered in Alzheimer’s disease. The paper supports heterogeneity and plasticity, but does not establish multiple transcriptional trajectories or show that its identified groups are nonpermanent. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Microglia in Alzheimer's disease appear to acquire hybrid programs: they remain tissue-resident myeloid cells but can express genes normally associated with professional antigen presentation, immune communication, and inflammatory coordination.

    “Instead, microglia in Alzheimer’s disease appear to acquire hybrid programs: they remain tissue-resident myeloid cells, but they can express genes normally associated with professional antigen presentation, immune communication, and inflammatory coordination.”
  • Single-cell and single-nucleus studies have identified Alzheimer's-associated microglial states enriched for immune activation, antigen-presentation genes, lipid-processing pathways, and inflammatory mediators.

    “Single-cell and single-nucleus studies have repeatedly identified Alzheimer ’s-associated microglial states enriched for immune activation, antigen-presentation genes, lipid-processing pathways, and inflammatory mediators.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Martins-Ferreira, R., Calafell-Segura, J., Leal, B., Rodríguez-Ubreva, J., Martínez-Saez, E., Mereu, E., Pinho E Costa, P., Laguna, A., & Ballestar, E.
Affiliations
  • Universidade do Porto (PT)
  • Josep Carreras Leukaemia Research Institute (ES)
  • Universitat Autònoma de Barcelona (ES)
Corresponding author
Ballestar, Esteban
Venue
Nature Communications
Published
2025-01-16
Volume
16
Issue
1
Pages
739-739
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4406437527
Cited by
123
References
77
Citations by year
2026: 79 · 2025: 41 · 2024: 3
FWCI
43.29
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Funders
  • Centres de Recerca de Catalunya (501100011033, MCIN/AEI/10.13039/501100011033)
  • European Commission (MCIN /AEI/ 10.13039/501100011033, 10.13039/501100011033, 13039/501100011033, 501100011033, /AEI/10.13039/501100011033)
  • Generalitat de Catalunya (10.13039/501100011033, 501100011033, MCIN /AEI/10.13039/501100011033)
  • Ministerio de Ciencia e Innovación (MCIN/AEI/10, .13039/501100011033, 10.13039, / AEI/10, MCIN/AEI/10.13039/501100011033,, 10.13039/501100011033/, PID2020117212RB-I00, 501100011033, RYC2021, MCIN /AEI /10.13039, /AEI/10.13039/ 501100011033)
  • Fundació Institut de Recerca Hospital Universitari Vall d’Hebron
  • Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
  • Fundação para a Ciência e a Tecnologia (UIDB/00215/2020 and UIDP/00215/2020, MCIN/AEI/10.13039/501100011033/, LA/P/006/2020, SFRH/BD/137900/2018, 10.13039/501100011033, UIDB/00215/2020, UIDP/00215/2020)
  • Agència de Gestió d'Ajuts Universitaris i de Recerca (MCIN/AEI/10.13039/501100011033/, 10.13039/501100011033, 13039/501100011033)
  • Instituto de Salud Carlos III (MCIN/ AEI /10.13039/501100011033, /10.13039/501100011033, PI21/01603, AEI/10.13039/501100011033)
  • Agencia Estatal de Investigación (AEI//10.13039/501100011033/, 501100011033, 10.13039/501100011033, MCIN/AEI/10.13039/501 100 011 033, 13039, .13039/501100011033, 10.13039, AEI/10)
  • Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto
  • Institut de Recerca contra la Leucèmia Josep Carreras
  • NextGenerationEU
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
Keywords
microglia, disease-associated microglia, microglial subtypes, neuroinflammation, neurodegenerative diseases, Alzheimer's disease, multiple sclerosis, autism spectrum disorder, epilepsy, Lewy body disease, COVID-19 pandemic, GPNMB, single-nucleus RNA sequencing, single-cell RNA sequencing
MeSH terms
Autism Spectrum Disorder, RNA-Seq, COVID-19, Aged, Alzheimer Disease, Animals, Atlases as Topic, Brain, Female, Humans, Macrophages, Male, Middle Aged, Multiple Sclerosis, Microglia, Neurodegenerative Diseases, Lewy Body Disease, Single-Cell Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review